Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SECRET

Financiado

Cerrado

Exploitation of the SECRETory pathway for cancer therapy to address European res...

Exploitation of the SECRETory pathway for cancer therapy to address European research Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of triple-negative BC (TNBC) targeted therapies are not available and non-selective chemothera... ver más

30/09/2023

USTUTT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITY OF STUTTGART No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-09-30

MSCA-ITN-2019: Innovative Training Networks

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

USTUTT

758.37K€ | Lider

STICHTING AMSTERDAM UMC

531.24K€ | Participante

TAU

263.50K€ | Participante

Proyectos interesantes

HOLDING-HANDS

Medical Technol...

Applied Physics

2M€ Cerrado

PID2021-124632OB-I00

Medical Technol...

Cancer Research

230K€ Cerrado

MetResistance

Medical Technol...

Applied Physics

1M€ Cerrado

RTI2018-094130-B-I00

Medical Technol...

Applied Physics

133K€ Cerrado

P73CANCER

Medical Technol...

Applied Physics

1M€ Cerrado

HALLMARKS-TO-THERAPY

Medical Technol...

Applied Physics

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 49 meses Fecha Inicio: 2019-08-09
Fecha Fin: 2023-09-30

Líder del proyecto

UNIVERSITY OF STUTTGART No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of triple-negative BC (TNBC) targeted therapies are not available and non-selective chemotherapy is the only treatment option. Targeted therapy has been approved for the treatment of advanced CRC, but response rates are low and treatment is limited to a subgroup of patients. Also, TNBC and CRC patients are prone to develop metastases and have a poor prognosis underpinning the need for new targeted and broadly applicable therapeutic strategies. Tumor cell secretion contributes to hallmarks of cancer e.g. hyperproliferation, evasion of growth suppression, loss of cell polarity, activation of cell motility, invasion and metastasis, shaping of the tumor microenvironment through altered presentation of proteins and the secretome, and resistance to cell death. Dysregulated secretion is thus a driver of cancer progression and therefore holds promise as a general therapeutic target for the treatment of cancers. However, strategies to exploit the secretory pathway for therapeutic and diagnostic purposes are still in their infancy due to the incomplete understanding of how this pathway is regulated by aberrant signaling. The overall research objective of SECRET is to drive the understanding of the mutual regulation of the secretory pathway and signaling in cancer, which will serve as a platform to identify and interrogate novel diagnostic and therapeutic strategies. SECRET comprises 11 beneficiaries and 7 partner organizations from 9 countries. Coordinated by the University of Stuttgart, SECRET will train 15 talented ESRs in the field of translational cancer systems cell biology and systems medicine towards a career in industry or academia through a highly interdisciplinary and intersectoral research training programme and inspire them to exploit the SECRETory pathway as a treasure trove to design novel therapeutic strategies against cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores